Lumevoq
GS-LHON-CLIN-08
Phase 2 small_molecule active
Quick answer
Lumevoq for Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene is a Phase 2 program (small_molecule) at GenSight Biologics S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GenSight Biologics S.A.
- Indication
- Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active